Skip to main content
SpringerLink
Log in

Update on Clinical Utility of Continuous Glucose Monitoring in Type 1 Diabetes

  • Treatment of Type 1 Diabetes (M Pietropaolo, Section Editor)
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Since the early 2000s, continuous glucose monitoring (CGM) technology has advanced to become a standard of care in the treatment of type 1 diabetes. Unfortunately, CGM use is not commonly integrated into practice. This article will review the history, technology, and need for systematic training in CGM. Additionally, it will review recent clinical trial data demonstrating the benefits that CGM offers to all people with type 1 diabetes and the clinicians who care for them.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Abbreviations

AP:

Artificial pancreas

BC:

Bolus calculators

CGM:

Continuous glucose monitoring

MARD:

Mean absolute relative difference

SMBG:

Self monitoring of blood glucoseT1DM, Type 1 diabetes mellitus

YSI:

Yellow Springs Instrument 2300 STAT Plus Glucose Analyzer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Bailey TS, Grunberger G, Bode B, et al. American Association of Clinical Endocrinologists and American College of Endocrinology 2016 outpatient glucose monitoring consensus statement. Endocr Pract. 2016;22(2):231–61. A current review of glucose monitoring placing CGM in perspective.

    Article  PubMed  Google Scholar 

  2. Miller KM, Beck RW, Bergenstal RM, et al. Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. Diabetes Care. 2013;36:2009–14.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Christiansen M, Bailey T, Watkins E, et al. A new-generation continuous glucose monitoring system: improved accuracy and reliability compared with a previous-generation system. Diabetes Technol Theraputics. 2013;15(10):881–7. doi:10.1089/dia.2013.0077.

    Article  CAS  Google Scholar 

  4. Miller KM, Foster NC, Beck RW, et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D exchange clinic registry. Diabetes Care. 2015;38:971–8. doi:10.2337/dc15-0078.

    Article  PubMed  Google Scholar 

  5. Liebing C, Erbach M, Schnell O, Haug C, Freckmann G. Glucose monitoring with a newly developed sensor system-step and time analysis. Diabetes Stoffwechsel und Herz. 2016;25(1):23–9.

    Google Scholar 

  6. Blevins TC. Professional continuous glucose monitoring in clinical practice 2010. J Diabetes Sci Technol. 2010;4(2):440–56.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359:1464–76. doi:10.1056/NEJMoa0805017.

    Article  Google Scholar 

  8. Beck RW, Hirsch IB, Laffel L, et al. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care. 2009;32:1378–83. doi:10.2337/dc09-0108.

    Article  CAS  PubMed  Google Scholar 

  9. Radermecker RP, Saint Remy A, Scheen AJ, Bringer J, Renard E. Continuous glucose monitoring reduces both hypoglycaemia and HbA1c in hypoglycaemia-prone type 1 diabetic patients treated with a portable pump. Diabetes Metab. 2010;36(5):409–13.

    Article  CAS  PubMed  Google Scholar 

  10. Battelino T, Liabat S, Veeze HJ, et al. Routine use of continuous glucose monitoring in 10501 people with diabetes mellitus. Diabet Med. 2015;32(12):1568–74. doi:10.1111/dme.12825.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Heinemann L, Freckmann G. CGM Versus FGM; or, continuous glucose monitoring is not flash glucose monitoring. J Diabetes Sci Technol. 2015;9(5):947–50. doi:10.1177/1932296815603528.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Lee JM, Hirschfeld E, Wedding J. A Patient-Designed Do-It-Yourself Mobile Technology System for Diabetes: Promise and Challenes for a New Era in Medicine. JAMA. 2016;315(14):1447–148. doi:10.1001/jama.2016.1903.

    Article  CAS  PubMed  Google Scholar 

  13. Bailey TS, Zisser HC, Garg SK. Reduction in hemoglobin A1C with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technol Terpautics. 2007;9(3):203–10. doi:10.1089/dia.2007.0205.

    Article  CAS  Google Scholar 

  14. Garg SK, Schwartz S, Edelman SV. Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes. Diabetes Care. 2004;27(3):734–8.

    Article  PubMed  Google Scholar 

  15. Edelman SV, Bailey TS. Continuous glucose monitoring health outcomes. Diabetes Technol Ther. 2009;11(supplement 1):S68–74. doi:10.1089/dia.2009.0012.

    CAS  PubMed  Google Scholar 

  16. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Sustained benefit of continuous glucose monitoring on a1c, glucose profiles, and hypoglycemia in adults with type 1 diabetes. Diabetes Care. 2009;32(11):2047–9. doi:10.2337/dc09-0846.

    Article  PubMed Central  Google Scholar 

  17. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care. 2009;32(11):1947–53. doi:10.2337/dc09-0889.

    Article  PubMed Central  Google Scholar 

  18. Chase HP, Beck RW, Xing D, et al. Continuous glucose monitoring in youth with type 1 diabetes: 12-month follow-up of the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial. Diabetes Technol Therapeutics. 2010;12(7):507–15. doi:10.1089/dia.2010.0021.

    Article  CAS  Google Scholar 

  19. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363(4):311–20. doi:10.1056/NEJMoa1002853.

    Article  CAS  PubMed  Google Scholar 

  20. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care. 2011;34(11):2403–5. doi:10.2337/dc11-1248.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Slover RH, Welsh JB, Criego A, et al. Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatr Diabetes. 2012;13(1):6–11. doi:10.1111/j.1399-5448.2011.00793.x.

    Article  CAS  PubMed  Google Scholar 

  22. The Value of continuous glucose monitoring in patients with type 1 diabetes using multiple daily injections—diamond study—results and implications. Presented June 12, 2016 by Elena Toschi at the 76th Annual Scientific Sessions of the American Diabetes Association.

  23. Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369:224–32. doi:10.1056/NEJMoa1303576. This article demonstrates a reduction in hypoglycemia with CGM-triggered suspension of insulin delivery.

  24. Agrawal P, Zhong A, Welsh JB, et al. Retrospective analysis of the real-world use of threshold suspend feature of sensor-augmented insulin pumps. Diabetes Technol Theraputics. 2015;17(5):316–9. doi:10.1089/dia.2014.0257.

    Article  CAS  Google Scholar 

  25. Cryer PE. Hypoglycemia: the limiting factor in the glycaemic management of type 1 and type II diabetes. Diabetologia. 2002;45(7):937–48. doi:10.1007/s00125-002-0822-9.

    Article  CAS  PubMed  Google Scholar 

  26. Zaccardi F, Davies MJ, Dhalwani NN, et al. Trends in hospital admissions for hypoglycaemia in England: a retrospective, observational study. Lancet Diabetes Endocrinol. 2016;4(8):677–85.

    Article  PubMed  Google Scholar 

  27. American Diabetes Association. Economic costs of diabetes in the U.S in 2012. Diabetes Care. 2013;36(4):1033–46. doi:10.2337/dc12-2625.

    Article  PubMed Central  Google Scholar 

  28. Bronstone A, Graham C. The potential cost implications of averting severe hypoglycemic events requiring hospitalization in high-risk adults with type 1 diabetes using real-time continuous glucose monitoring. J Diabetes Sci Technol. 2016;10(4):905–13. doi:10.1177/1932296816633233.

    Article  PubMed  Google Scholar 

  29. Rodbard D. Continuous glucose monitoring: a review of successes, challenges, and opportunities. Diabetes Technol Ther. 2016;18(supplement 2):S2-3–S2-13. doi:10.1089/dia.2015.0417.

    Article  Google Scholar 

  30. Bloomgarden DK, Freeman J, DeRobertis E. Early patient and clinical experiences with continuous glucose monitoring. Diabetes Spectrum. 2008;21(2):128–33.

    Article  Google Scholar 

  31. Wolpert H. Establishing a continuous glucose monitoring program. J Diabetes Sci Technol. 2008;2(2):307–10.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Walsh J, Roberts R. Pumping insulin: everything for success on an insulin pump and CGM. 6th ed. San Diego: Torrey Pines Press; 2016 [A primer on CGM and pump optimization for both clinicians and patients].

  33. Vahdat S, Hamzehgardeshi L, Hessam S, et al. Patient involvement in health care decision making: a review. Iran Red Crescent Med J. 2014;16(1):e12454. doi:10.5812/ircmj.12454.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Shivers JP, Mackowiak L, Anhalt H, et al. “Turn it off!”: diabetes device alarm fatigue considerations for the present and the future. J Diabetes Sci Technol. 2013;7(3):789–94. doi:10.1177/193229681300700324.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Pettus J, Edelman S. Recommendations for using real-time continuous glucose monitoring (rtCGM) data for insulin adjustments in type 1 diabetes. J Diabetes Sci Technol. 2016. doi:10.1177/1932296816663747. This reference describes a novel approach to insulin dosing using CGM trend arrows.

  36. Gehr B, Holder M, Kulzer B, Lange K, Liebl A, Sahm C, et al. SPECTRUM: a training and treatment program for continuous glucose monitoring for all age groups. J Diabetes Sci Technol. 2016. doi:10.1177/1932296816661735.

  37. Maahs DM, DeSalvo D, Pyle L, et al. Effect of acetaminophen on CGM glucose in an outpatient setting. Diabetes Care. 2015;38(10):e158–9. doi:10.2337/dc15-1096.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Mensh BD, Wisniewski NA, Neil BM, et al. Susceptibility of interstitial continuous glucose monitor performance to sleeping position. J Diabetes Sci Technol. 2013;7(4):863–70. doi:10.1177/193229681300700408.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Gough DA, Kumosa LS, Routh TL, et al. Function of an implanted tissue glucose sensor for more than 1 year in animals. Sci Transl Med. 2010;2(42):42–53. doi:10.1126/scitranslmed.3001148.

    Article  Google Scholar 

  40. Dehennis A, Mortellaro MA, Ioacara S. Multisite study of an implanted continuous glucose sensor over 90 days in patients with diabetes mellitus. J Diabetes Sci Technol. 2015;9(5):951–6. doi:10.1177/1932296815596760.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile. J Diabetes Sci Technol. 2013;7:562–78. This article proposes a standard to report CGM data.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Food and Drug Administration. Brief summary of the clinical chemistry and clinical toxicology devices panel meeting July 21, 2016. Department of Health & Human Services. 2016.

    Google Scholar 

  43. Trevitt S, Simpson S, Wood A. Artificial pancreas device systems for the closed-loop control of type 1 diabetes: what systems are in development? J Diabetes Sci Technol. 2016;10(3):714–23. doi:10.1177/1932296815617968.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Advanced Metabolic Care and Research, 625 W. Citracado Pkwy, Ste 108, Escondido, CA, 92025, USA

    Nalani Haviland & John Walsh

  2. Diabetes Services, Inc., 1030 West Upas St., San Diego, CA, 92103, USA

    Ruth Roberts

  3. AMCR Institute, 625 West Citracado Parkway Suite 112, Escondido, CA, 92025, USA

    Timothy S. Bailey

Authors
  1. Nalani Haviland
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Walsh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ruth Roberts
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Timothy S. Bailey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy S. Bailey.

Ethics declarations

Conflict of Interest

Timothy Bailey reports research support from Abbott, ACON, Ascensia, BD, Boehringer Ingelheim, Companion Medical, Dexcom, Elcelyx, Glysens, Insulet, Janssen, Lexicon, Lifescan, Lilly, Medtronic, Merck, Novo Nordisk, Sanofi, Senseonics, Versartis, and Yofimeter. He reports consulting honoraria from Ascensia, Astra Zeneca, BD, Calibra, Lilly, Medtronic, Novo Nordisk, Sanofi Speaking Honoraria: Abbott, Insulet, Medtronic, Novo Nordisk, and Sanofi. John Walsh reports that he has received consultant fees from ACON Laboratories, Abbott Laboratories, Animas Corporation, Becton, Dickinson and Company, Lifescan Inc., and Tandem Diabetes Care; speaker honoraria from Animas Canada, Becton, Dickinson and Company, Dexcom, and Sanofi K.K.; and advisory board honoraria from Becton, Dickinson and Company, ConvaTec, Inc., Halozyme, Inc., and Tandem Diabetes. He is also a consultant for a number of companies developing insulin pumps and infusion sets. He is employed by Advanced Metabolic Care and Research, which conducts numerous studies in diabetes devices, medications, infusion sets, and insulins. Nalani Haviland and Ruth Roberts declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Treatment of Type 1 Diabetes

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Haviland, N., Walsh, J., Roberts, R. et al. Update on Clinical Utility of Continuous Glucose Monitoring in Type 1 Diabetes. Curr Diab Rep 16, 115 (2016). https://doi.org/10.1007/s11892-016-0808-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11892-016-0808-5

Keywords

Search

Navigation